Department of Medicine 5 – Haematology and Oncology

Extracellular Vesicles of CLL Cells affect T-Cell Activation and promote their Depletion via diverse immunological Checkpoints (2022) Boettcher M, Boettcher-Loschinski R, Gießl A, Schlötzer-Schrehardt U, Bruns H, Mougiakakos D Conference contribution Interprofessionelle Kommunikation uber,Complementary and Integrative Health" (CIH): Entwicklung und Implementierung eines Training-Programms (2022) Behzad A, Stein B, Schmitt A, Lohmuller L, Kroger B, Boltenhagen U, Joos S, et al. Conference contribution Single-cell Transcriptome Analysis and clonal Kinetics in a Patient after CD19.CAR-T Cell Therapy (2022) Lischer C, Eisenhauer N, Aigner M, Jacobs B, Schletter M, Gebhard C, Rehli M, et al. Conference contribution CXCR2 expression on neutrophil granulocytes in peripheral tumor is associated with shorter survival in oral squamous cell carcinoma (2022) Spörl S, Erber R, Gerken M, Wittenberg M, Fischer R, Taxis J, Hartmann A, et al. Conference contribution Targeted Inhibition of Protein Biosynthesis sensitizes Cancer Cells to IRE1a-mediated Apoptosis as a Consequence of the unfolded protein response (2022) Gsottberger F, Meier C, Ammon AM, Parker S, Wendland K, George R, Petkovic S, et al. Conference contribution Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution Immunometabolic alteration in NK cells from multiple myeloma patients (2022) Jacobs B, Richter S, Stoll A, Völkl S, Mackensen A, Mougiakakos D Conference contribution Functional characterization of CD34(+) cells from cryopreserved apheresis of patients with bone marrow-infiltrating malignancies (2022) Wendland K, Petkovic S, Aigner M, Strobel J, Müller F Conference contribution Lipotoxicity as a Barrier for T Cell-Based Therapies (2022) Boettcher-Loschinski R, Rial Saborido J, Boettcher M, Kahlfuss S, Mougiakakos D Journal article, Review article Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial (2022) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duehrsen U, Hahn D, Meidenbauer N, et al. Journal article